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Abstract: RASSF1 gene methylation predicts longer disease-free survival (DFS) and overall survival 
(OS) in patients with early-stage non-small-cell lung cancer treated using paclitaxel-based neo-
adjuvant chemotherapy compared to patients receiving a gemcitabine-based regimen, according to 
the randomized Phase 3 IFCT (Intergroupe Francophone de Cancérologie Thoracique)-0002 trial. To 
better understand these results, this study used four human bronchial epithelial cell (HBEC) models 
(HBEC-3, HBEC-3-RasV12, A549, and H1299) and modulated the expression of RASSF1A or YAP-
1. Wound-healing, invasion, proliferation and apoptosis assays were then carried out and the 
expression of YAP-1 transcriptional targets was quantified using a quantitative polymerase chain 
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reaction. This study reports herein that gemcitabine synergizes with RASSF1A, silencing to increase 
the IAP-2 expression, which in turn not only interferes with cell proliferation but also promotes cell 
migration. This contributes to the aggressive behavior of RASSF1A-depleted cells, as confirmed by 
a combined knockdown of IAP-2 and RASSF1A. Conversely, paclitaxel does not increase the IAP-2 
expression but limits the invasiveness of RASSF1A-depleted cells, presumably by rescuing 
microtubule stabilization. Overall, these data provide a functional insight that supports the 
prognostic value of RASSF1 gene methylation on survival of early-stage lung cancer patients 
receiving perioperative paclitaxel-based treatment compared to gemcitabine-based treatment, 
identifying IAP-2 as a novel biomarker indicative of YAP-1-mediated modulation of chemo-
sensitivity in lung cancer. 
Keywords: Non-small-cell lung cancer; RASSF1A; DNA methylation; paclitaxel; IAP2 
 
1. Introduction 
Over the last few years, targeted therapy based on specific predictive biomarkers has improved 
both the survival rate and quality of life of cancer patients [1,2]. Among the predictive biomarkers in 
patients with non-small-cell lung cancer (NSCLC), the promoter hyper-methylation of the tumor 
suppressor gene RASSF1A is still misused. However, the results of the Phase 3 IFCT (Intergroupe 
Francophone de Cancérologie Thoracique)-0002 randomized trial demonstrated both the prognostic 
and predictive values of RASSF1A gene silencing, following neo-adjuvant chemotherapy in patients 
with Stage I–II NSCLC [3]. The patients with RASSF1A promoter gene methylation displayed a three-
fold decrease in the 5-year overall survival (OS) rate [3]. Additionally, a worse median OS was 
observed in patients with methylated RASSF1A treated with gemcitabine (30.3 months) compared to 
those treated with paclitaxel (70 months) [3]. These prognostic values of RASSF1A gene methylation 
were supported by data that demonstrated that RASSF1A restricts epithelial-mesenchymal transition 
(EMT) and cell invasion by controlling Yes-associated protein (YAP) nuclear shuttling and RhoB-
regulated cytoskeletal remodeling process [4,5]. As such, RASSF1A inactivation favors the acquisition 
of a metastatic phenotype that explains these patients. However, how RASSF1A epigenetic silencing 
contributes to the positive effects of paclitaxel versus gemcitabine treatment has yet to be determined 
[3]. To be able to rationally develop enhanced treatment strategies, it is imperative to define whether 
RASSF1A depletion enhances sensibility to paclitaxel or, to the contrary, increases the patient’s 
resistance to gemcitabine-induced cell death.  
Paclitaxel is a tubulin-stabilizing agent that leads to mitotic arrest, while gemcitabine is a 
cytosine analogue that inhibits nucleoside metabolism, both ultimately causing cell death [6,7]. Both 
drugs have become key components in the treatment of advanced NSCLC patients, being given 
mostly in combination with platinum compounds [8,9] prior to the introduction of immune 
checkpoint inhibitors (ICI) for managing Stage IV NSCLC patients. This triple combination 
(platinum-based chemotherapy and ICI) is being currently tested in a neo-adjuvant setting. Based on 
post-hoc biomarker analyses of clinical trials, the predominant hypothesis explaining such data 
would be that paclitaxel mimics RASSF1A-induced microtubule stabilization. However, numerous 
studies have also demonstrated the relevance of RASSF1A’s association with microtubules and 
members of the Hippo pathway in the apoptosis process [10–12]. As such, RASSF1A depletion may 
lead to the cells’ resistance to apoptosis, along with the subsequent ineffectiveness of 
chemotherapeutic agents. This resistance accounts for difficulties in the management of numerous 
cancers, due to either cellular adaptation to stress or an increase in anti-apoptotic proteins, such as 
the YAP-1 transcriptional target inhibitor of apoptosis protein (IAP) [13]. Indeed, through their three 
baculovirus IAP repeat (BIR) domains, IAPs bind to and inhibit caspases, which act as the terminal 
effectors of apoptosis [14,15]. However, IAPs represent a highly versatile class of proteins that 
regulate not only apoptosis but also various biological functions, including innate immunity, 
inflammation, cell proliferation and cell migration [16–20]. Some members of the IAP family, such as 
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IAP-1 and IAP-2, have been reported to be overexpressed in several cancers, including lung cancer 
[21–24]. 
As some IAP family members were reported to be transcriptional targets of Yorkie, YAP 
drosophila ortholog [13], the activity of which is increased and deregulated in RASSF1A-depleted 
NSCLC cells [4], this study hypothesized that IAPs could underlie the predictive value of RASSF1A 
promoter methylation. By using either RNAi to mimic RASSF1A methylation in NSCLC or RASSF1A-
encoding plasmid in rescue experiments, this study provided molecular insights into the prognostic 
value of RASSF1A and how its depletion would possibly affect the efficiency of chemotherapeutic 
agents like paclitaxel and gemcitabine. Moreover, IAP-2 as a novel putative biomarker was 
introduced for choosing paclitaxel rather than gemcitabine for the platinum-based doublets, which 
are still used as perioperative treatments in patients with early-stage NSCLC and silenced RASSF1A. 
2. Results 
2.1. RASSF1A Depletion Suppresses Cell Sensitivity to Drug-Induced Apoptosis 
RASSF1A’s role was first investigated in modulating apoptosis in response to chemotherapeutic 
agents, such as paclitaxel and gemcitabine, using non tumorigenic and untransformed but immortalized 
bronchial HBEC-3 and HBEC-3 RasV12 cell lines [25], in order to mimic the early loss of RASSF1A 
expression in lung epithelial carcinogenesis [26]. RASSF1A was depleted using two different small 
interfering RNAs (siRNA), leading to 70% and 80% decreases in RASSF1A mRNA and protein levels, 
respectively (HBEC-3: Figure S1A–B; HBEC-3 RasV12: Figure S1C–D), as previously reported [4]. The 
cancer-derived A549 and H1299 cell lines with RASSF1A promoter gene methylation were additionally 
used and no basal RASSF1A protein expression in rescue experiments in order to confirm the specificity 
of our RNA-interference (RNAi) results. Accordingly, RASSF1A was reintroduced using a RASSF1A-
encoding expression plasmid (H1299: Figure S2A; A549: Figure S2B). 
Twenty-four hours after being transfected with the constructs (control RNAi [siNeg], 
siRASSF1A-1 or -2, control [Pls Ctr] and RASSF1A-encoding plasmids [Pls RASSF1A]), the cells were 
treated with either paclitaxel (10 nM) or gemcitabine (250 nM) for another 24 hours (Figure 1). 
Etoposide (50 µM) was employed as an apoptosis inducer and a positive control for drug efficacy 
[27]. As expected, the control cells’ (siNeg or Pls Ctr) exposure to either paclitaxel or gemcitabine 
caused a significant increase in caspase 3/7 activities, cytochrome c release and DNA fragmentation 
after the cells were treated with chemotherapy (HBEC-3: Figure 1A, C–D; HBEC-3 RasV12: Figure 
1B–E; H1299: Figure S2A; and A549: Figure S2B, respectively). With the exception of A549 cells, in 
our experimental conditions, paclitaxel was more likely to induce apoptosis than gemcitabine (HBEC-
3: Figure 1A,C,D; HBEC-3 RasV12: Figure 1B–E; H1299: Figure S2A; and A549: Figure S2B). 
Following RASSF1A knockdown in untreated HBEC-3 and HBEC-3 RasV12 cell lines, this study 
did not observe any significant differences in caspase 3/7 activities (HBEC-3: Figure 1A; HBEC-3 
RasV12: Figure 1B) or DNA fragmentation (HBEC-3: Figure 1D; HBEC-3 RasV12: Figure 1E). 
However, surprisingly, RASSF1A silencing dramatically reduced the effect of paclitaxel treatment on 
both caspase 3/7 activities and DNA fragmentation (HBEC-3: Figure 1A–D; HBEC-3 RasV12: Figure 
1B–E). 
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Figure 1. RASSF1A depletion suppresses cell sensitivity to drug-induced apoptosis. HBEC-3 cells 
were transfected with siNeg or siRASSF1A. The 24-hour post-transfection cells were treated for a 
further 24 h with paclitaxel (10 nM) or gemcitabine (250 nM). A–B) The effect of RASSF1A depletion 
on caspase-3/7 activity was measured by Caspase-Glo® 3/7 Assay kit in (A) HBEC-3 and (B) HBEC-
RasV12 cells undergoing apoptosis using paclitaxel or gemcitabine treatment. (C) The effects of 
RASSF1A depletion on cytochrome C expression were observed by immunofluorescence in HBEC-3 
cells undergoing apoptosis induced by paclitaxel or gemcitabine treatment. Magnification: objective 
×60. (D–E) The effects of RASSF1A depletion on DNA fragmentation were measured in (D) HBEC-3 
and (E) HBEC-RasV12 cells undergoing apoptosis induced by paclitaxel or gemcitabine treatment. 
The data are expressed as the mean ± SEM from three individual experiments. The statistical 
significance was determined by a Student’s t–test: * p < 0.05; ** p < 0.01; *** p < 0.001. 
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Consistently, the exogenous expression of RASSF1A in H1299 and A549 cells, which display no 
detectable basal expression of RASSF1A, did not influence caspase3/7 activities (H1299: Figure S2A; 
A549: Figure S2B). However, paclitaxel either tended to increase (A549) or increase (H1299) the 
efficiency of caspase 3/7 activities following the reintroduction of RASSF1A (H1299: Figure S2A; A549: 
Figure S2B). 
Altogether, these data indicate that RASSF1A knockdown reduces cell sensitivity to drug-
induced apoptosis. 
2.2. RASSF1A Depletion Coincides with Strong YAP-Dependent IAP-2 Expression 
The authors have previously demonstrated that the loss of RASSF1A expression leads to the 
inappropriate activity of YAP, the subcellular localization of which becomes preferentially nuclear 
and coincides with an increase in the transcription of several target genes [4,5,28]. Some IAPs, 
proteins acting as negative apoptosis regulators by inhibiting the activity of several caspases [29], 
could also be the transcriptional targets of YAP as shown in drosophila [13]. The impact of RASSF1A 
levels was then tested on the expression of different IAPs (Figure 2). It was found that RASSF1A-
depleted HBEC-3 cells exhibited a significant increase in IAP-2 mRNA expression, while there were 
no changes in the IAP-1, XIAP, or Bruce mRNA levels (Figure 2A). Conversely, the exogenous 
expression of RASSF1A in A549 and H1299 cells significantly reduced the IAP-2 mRNA expression 
levels compared to those of the control cells transfected with a mimic plasmid (H1299: Figure 2B; 
A549: Figure 2C). Here, the absence or presence of RASSF1A again had no effect on the other 
apoptosis inhibitor levels (H1299: Figure 2B; A549: Figure 2C). Next, by co-transfection of the HBEC-
3 cells with YAP and RASSF1A RNAi, it was further confirmed that the YAP transcriptional activity 
was responsible for IAP-2 expression in RASSF1A-depleted cells (Figure 2D). 
 
Figure 2. RASSF1A modulates IAP-2 expression. HBEC-3 cells were transiently transfected with 
siNeg and siRASSF1A-1, whereas A549 and H1299 cells were transfected with plasmid coding wild-
type RASSF1A. (A–C) mRNA expression of IAP-1, IAP-2, surviving, and Bruce was examined by RT-
PCR in (A) HBEC-3, (B) H1299, and (C) A549. S16 was used as an internal control. (D) mRNA 
expression of IAP-2 was examined using RT-PCR in HBEC-3 cells that were transiently transfected 
with siNeg and siRASSF1A-1 both in combination with and without siYAP. S16 was used as an 
internal control. The data are expressed as the mean ± SEM from three individual experiments. The 
statistical significance was determined by a Student’s t-test. * p < 0.05; ** p < 0.01; *** p < 0.001. 
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It was thus assumed that RASSF1A depletion leading to YAP activation could decrease cancer 
cell apoptosis by increasing the expression of the inhibitor of apoptosis protein IAP-2. 
2.3. Strong YAP Intensity Associated with a Weak Response Rate to Chemotherapy in NSCLC Patients from 
the IFCT-0002 Trial 
To investigate whether YAP expression is involved in NSCLC patients’ responses to 
chemotherapy, the status and subcellular localization of YAP were evaluated in the available samples 
from 528 patients included into the Phase III clinical Bio-IFCT0002 cohort [3] (Figure S3). The sections 
of formalin-fixed, paraffin-embedded tissue samples were immunostained using a YAP antibody, 
with the YAP expression determined via an H-score method (intensity score (Figure S3A) × 
percentage of positive tumoral cells). The analyses of 362 out of the 443 available tumor samples were 
informative for YAP immunostaining (Figure S3B). Overall, 43 tumor samples (11.9%) were YAP 
negative, 245 (67.6%) had mild to moderate YAP intensity and 74 (20.4%) had high YAP intensity. 
The subcellular localization of YAP occurred exclusively in the cytoplasm in 21.3% of cases, 
exclusively in the nucleus in 51.7% and across the cytoplasm and nucleus in 27% of cases. The median 
immunostaining H-score was 80. 
The univariate analysis revealed no prognostic impact of YAP intensity on NSCLC patient 
survival (Figure S3C), while the localization of YAP within the cytoplasm, where YAP is sequestered 
or prone to proteasome degradation, tended to predict longer OS. However, without reaching 
statistical significance (Figure S3D, p = 0.24, median survival of ~65 months versus >110 months for 
patients with nuclear YAP), in addition to longer progression-free survivals (PFS) of these patients (p 
= 0.2, median survival of ~42 months versus 32 months for patients with nuclear YAP). As the authors 
suspected a lack of statistical power due to the attrition of the numbers of available pathological 
samples from the IFCT-0002 cohort, the survival data was further analyzed following resections from 
early-stage lung cancer patients from the publicly available Cancer Tumor Genome Atlas (CTGA) 
cohort. This analysis revealed that a high mRNA expression was associated with worse OS rates of 
NSCLC patients (Figure S3E). 
Finally, YAP intensity was reported to be associated with objective responses (partial or 
complete) of early-stage NSCLC patients treated with preoperative chemotherapy in the IFCT-0002 
trial (Table 1): Overall, 63 of the 356 (17.7%) patients studied in this trial showed no response and did 
not express or expressed low (0–1 intensities) tumoral YAP levels (37.6% [63/134] of patients with low 
YAP intensity tumor), while 135 patients showed no response and a strongly expressed YAP tumor 
intensity (60.81% [135/222] of patients with strong tumoral intensity of YAP) (chi2 p-value = 0.011). 
Table 1. Correlation of YAP expression with the responses to chemotherapy of 363/528 non-small-cell 
lung cancer (NSCLC) patients from the IFCT-0002 trial. 
YAP Intensity 
Response 
Total 
Complete or Partial In Progress or Non-Evaluable 
0 or 1 
n = 71 n = 63 n = 134 
(19.94%) (17.70%) (37.64%) 
2 or 3 
n = 87 n = 135 n = 222 
(24.44%) (37.92%) (62.36%) 
Total 
n = 158 n = 198 n = 356 
(44.38%) (55.62%) (100%) 
  p value (Chi-squared association) = 0.011   
Therefore, it was postulated that the RASSF1A depletion leading to YAP activation likely 
decreases cancer cells’ apoptosis by increasing the expression of the inhibitor of the apoptosis IAP-2 
protein. This rationale supports the observation that strong YAP expression was associated with a 
high progression rate in NSCLC patients from the IFCT-0002 trial. 
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2.4. Gemcitabine Treatment Synergizing the Increased IAP-2 Expression Induced by RASSF1A Depletion 
Given that several commonly used antineoplastic drugs are able to increase IAPs’ expression 
[29,30], this study then evaluated the impact of paclitaxel and gemcitabine treatments on the IAP-2 
levels present in or absent from RASSF1A gene expression. It was observed that gemcitabine 
treatment alone caused a significant increase in IAP-2 expression in HBEC-3 control cells. In 
combination with RASSF1A RNAi depletion, gemcitabine treatment exerted a cumulative effect 
(Figure 3A). In contrast, the co-treatment by paclitaxel and RASSF1A RNAi knockdown on IAP-2 
expression was comparable in their effects to that of RASSF1A-depleted cells alone (Figure 3A). 
 
Figure 3. Gemcitabine treatment coincides with strong IAP-2 expression following RASSF1A 
depletion. HBEC-3 cells were transiently transfected with siNeg and siRASSF1A-1, whereas A549 and 
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H1299 cells were transfected with plasmid coding wild-type RASSF1A. When indicated, 24-hour post-
transfection cells were treated for a further 24 h with paclitaxel (10 nM), gemcitabine (250 nM), or 
etoposide (50 µM). (A–C) mRNA expression of IAP-2 was examined using RT-PCR in (A) HBEC-3, 
(B) H1299, and (C) A549. S16 was employed as internal control. The data are expressed as the mean ± 
SEM from three individual experiments. The statistical significance was determined using a Student’s 
t-test. * p < 0.05; ** p < 0.01; *** p < 0.001. 
Consistently, treating the H1299 cells with the methylated RASSF1A gene using gemcitabine 
alone significantly increased IAP-2 mRNA levels (Figure 3B), while the authors did not observe any 
IAP-2 mRNA expression changes in A549 RASSF1A methylated cells treated with either paclitaxel or 
gemcitabine (Figure 3C). Furthermore, whereas the ectopic expression of RASSF1A significantly 
reduced IAP-2 mRNA levels in both lines, the simultaneous cell transfection with RASSF1A plasmid 
and gemcitabine treatment had an additive effect on the reduced IAP-2 expression (H1299: Figure 
3B; A549: Figure 3C). Intriguingly, the transfection of the H1299 and A549 cells with RASSF1A 
plasmid along with paclitaxel treatment did not change the IAP-2 levels compared to either the 
control or paclitaxel-treated cells alone. 
Therefore, this study postulated that gemcitabine treatment specifically synergizes the IAP-2 
expression increase induced by RASSF1A depletion. 
2.5. IAP-2 Interfering with RASSF1A-Mediated Cell Proliferation 
Furthermore, IAPs prevent apoptosis by inhibiting caspase activation, thereby interfering with 
cell proliferation and survival [18,31]. To investigate whether RASSF1A-dependent modulation of 
IAP expression could affect proliferation and apoptosis, the cells were transfected with different 
combinations of RASSF1A constructs and IAP-1 and two siRNAs. Both RNAi resulted in the efficient 
decrease in IAP-1 or IAP-2 mRNA expression by 80–90% in HBEC-3 (Figure S4A), H1299 (Figure S4B) 
and A549 (Figure S4C) cell lines. 
The cells first underwent a proliferation analysis using bromodeoxyuridine (BrdU) 
incorporation assays. As shown in Figure 4A, HBEC-3 cell proliferation significantly decreased 
following RASSF1A depletion, whereas neither siIAP-1 nor siIAP-2 alone had any influence on cell 
proliferation (Figure 4A). Remarkably, the concomitant RASSF1A and IAP-2 depletion was shown to 
rescue the RASSF1A-depleted cells’ proliferation defect (Figure 4A). In contrast, a combined 
knockdown of RASSF1A and IAP-1 RNAi had no impact on the reduced cell proliferation induced 
by RASSF1A depletion in HBEC-3 cells (Figure 4A). 
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Figure 4. IAP-2 interferes with RASSF1A-mediated cell proliferation. HBEC-3 cells were transiently 
transfected with siNeg and siRASSF1A-1, whereas A549 and H1299 cells were transfected with 
plasmid coding wild-type RASSF1A. (A–C) Cell proliferation was assessed using BrdU incorporation 
and subsequent spectrophotometric detection at 450 nm wavelength in (A) HBEC-3, (B) H1299, and 
(C) A549. The data are expressed as the mean ± SEM from three individual experiments. The statistical 
significance was determined using a Student’s t-test. * p < 0.05; ** p < 0.01. 
Moreover, exogenous RASSF1A expression caused a slight decrease in cell proliferation in 
H1299 cells (Figure 4B) and A549 cells (Figure 4C), the difference achieved being statistically 
significant only in A549 cells (Figure 4C). This reflects the necessity of appropriate RASSF1A levels 
for efficient cell proliferation [5,32]. To the authors’ surprise, in both H1299 and A549 cells, a single 
IAP-2 knockdown or a combined IAP-2 knockdown with RASSF1A re-expression caused a modest 
but significant reduction in cell proliferation (Figure 4B–C). This inhibitory effect on proliferation was 
also observed in A549 cells following the transfection of IAP-1 RNAi and RASSF1A plasmids (Figure 
4C). Hence, it was postulated that IAP-2 could interfere with RASSF1A-mediated cell proliferation. 
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2.6. Increased IAP-2 Expression both Necessary and Sufficient for siRASSF1A-Induced Increase in Cell 
Migration and Invasion 
The increased migration and invasiveness are striking hallmarks of cancer cells [33]. A body of 
evidence supports IAPs to play a critical role in regulating cell migration and metastasis [34,35]. Since 
RASSF1A controls both cell migration and invasion [4,36], IAPs’ involvement in these processes was 
next explored. Consistent with our previous experiments, a wound-healing assay revealed the 
increased migration of RASSF1A-depleted HBEC-3 cells compared to that of the controls (Figure 5A), 
whereas RASSF1A re-expression was associated with a significant reduction in migration distances 
of H1299 and A549 cells lines (Figure 5C and Figure S5A). Further results in HBEC-3 cells revealed 
that, compared to the depletion of either IAP-1 or IAP-2 alone exhibiting no effect on migration 
velocity in control cells (siNeg) with normal RASSF1A expression, a combined knockdown of IAP-1 
and RASSF1A or IAP-2 and RASSF1A significantly decreased the siRASSF1A-induced enhancement 
of cell migration (Figure 5A). Accordingly, IAP-1 silencing did not affect the migration velocity of 
H1299 and A549 cells either expressing or not RASSF1A, whereas IAP-2 silencing significantly 
decreased such migration velocity of H1299 and A549 cells either expressing or not (Figure 5C and 
Figure S5A). These data prompted us to postulate that increased IAP-2 expression following 
RASSF1A depletion could be necessary for the observed increment in cell migration. 
Next, the Matrigel®-coated Transwell 3D migration was exploited. As expected, based on our 
previous results, RASSF1A depletion effectively promoted cell invasion through Matrigel® in HBEC-
3 cells (Figure 5B). In contrast, exogenous RASSF1A expression significantly reduced H1299 and A549 
cells’ 3D migration and invasion through Matrigel® (Figure 5D and Figure S5B). Remarkably, IAP-1 
depletion alone was accompanied by a similar increase in HBEC-3 cell invasiveness. However, a 
combined RASSF1A and IAP-2 depletion dramatically blocked the siRASSF1A-induced invasion 
(Figure 5B). Here, the elimination of endogenous IAP-2 from both H1299 and A549 cells lines caused 
a reduction in the invasive capacity of either the control or RASSF1A re-expressed cells to the level 
observed in cells transfected with exogenous RASSF1A (Figure 5D and Figure S5B), whereas IAP-1 
depletion only affected the 3D migration of H1299 cells (Figure 5D). 
Considering the IAP-2 reduction in cells transfected with RASSF1A plasmid (Figure 2B,C), these 
data support IAP-2 to possibly represent a critical downstream target of RASSF1A for controlling cell 
migration and invasion. 
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Figure 5. The increase of IAP-2 expression is critical for RASSF1A-mediated effects on cell migration 
and invasion. HBEC-3 cells were transiently transfected with siNeg and siRASSF1A-1, whereas A549 
and H1299 cells were transfected with plasmid coding wild-type RASSF1A both in and without 
combination with siRNA targeting IAP-1 and IAP-2, (as indicated on x-axis). (A,C) Migration speed 
(µm/h) was assessed by the wound-healing assay in (A) HBEC-3 (scale bar, 100 µm) and (C) H1299 
cells (Scale bar, 200 µm). (B) Invasion capacity of transfected HBEC-3 cells was measured using 
Matrigel®-coated Invasion Transwell. Relative invasion normalized to that of the cells transfected with 
siNeg. Scale bar: 50 µm. (D) 3D Migration capacity was measured using Transwell without any 
coating. Relative invasion normalized to that of the cells transfected with control mimic plasmid. Scale 
bar: 50 µm. The data were expressed as the mean ± SEM from three individual experiments. The 
statistical significance was determined using a Student’s t-test. * p < 0.05; ** p < 0.01; *** p < 0.001. 
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2.7. Paclitaxel Treatment Rescuing Normal Invasion Following RASSF1A Knockdown 
RASSF1A controls cell migration and invasion by its association with microtubules, resulting in 
their stabilization [37,38]. Paclitaxel also binds reversibly to microtubules, and the resulting 
microtubules are stable and resistant to tubulin depolymerization [39]. Given that RASSF1A 
depletion induces microtubule destabilization and therefore increases cell migration and invasion [4], 
it was queried whether paclitaxel could rescue these effects if microtubule stability increased. To 
explore this possibility, this study compared the effect of paclitaxel and gemcitabine alone or in 
combination with either siRASSF1A or plasmids encoding wild-type RASSF1A on cell invasion 
ability. 
In agreement with previous data [4], a significant increase in the cell invasion ability of HBEC-3 
RASSF1A-depleted cells were found, whereas, conversely, RASSF1A overexpression following 
HBEC-3 cell transfection of an RASSF1A-encoding plasmid caused a significant decrease in cell 
invasion (Figure 6). Remarkably, compared to untreated controls and gemcitabine-treated cells, 
paclitaxel exposure was found to be able to restore basal invasion capacities in RASSF1A-knockdown 
cells (Figure 6). Based on these results, normal microtubule dynamics per se proved to be sufficient 
for the efficient invasion properties of cells. 
 
Figure 6. Paclitaxel treatment rescues normal invasion following RASSF1A knockdown. HBEC-3 cells 
were transiently transfected with siNeg, siRASSF1A, or plasmid coding wild-type RASSF1A. When 
indicated, 24-hour post-transfection cells were treated for a further 24 h with paclitaxel (10 nM) or 
gemcitabine (250 nM). The invasion capacity of transfected HBEC-3 cells was measured using 
Matrigel®-coated Invasion Transwell. Relative invasion normalized to that of the cells transfected with 
siNeg. Scale bar: 50 µm. The data are expressed as the mean ± SEM from three individual experiments. 
The statistical significance was determined using a Student’s t-test. * p < 0.05; ** p < 0.01. 
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3. Discussion 
The authors were intrigued to further understand how the RASSF1A expression loss could 
predict either the effectiveness of pre-operative taxol-based therapy or the failure of pre-operative 
gemcitabine treatment in patients with early-stage NSCLC from the Phase 3 IFCT-0002 trial, as 
reported in detail in our previous work [3]. Herein, some evidence was provided supporting that 
gemcitabine synergizes with the RASSF1A silencing in human epithelial immortalized bronchial cells 
(HBEC) in order to increase IAP-2 expression. This latter, in turn, interferes with cell proliferation, 
promotes cell migration and thus contributes to the aggressive behavior of such RASSF1A-depleted 
cells. Conversely, paclitaxel does not interfere with IAP-2 expression, and thus contributes efficiently 
to limit cell migration and subsequent metastatic potential, which accounts for the survival effect of 
RASSF1A promoter gene methylation in paclitaxel-treated NSCLC patients (Graphical abstract). 
A major mode of action of chemotherapeutic drugs is to provoke apoptosis [40], whereas 
RASSF1A is a well-established regulator of apoptosis [41]. Thus, the authors first decided to evaluate 
the activity of the known downstream proteins of the apoptotic pathway in HBEC, with and without 
RASSF1A expression [42]. This study chose to use the non tumorigenic and untransformed (yet 
immortalized) bronchial HBEC-3 and HBEC-3 RasV12 cell lines [25] so as to mimic the early-stage 
loss of RASSF1A expression in lung pre-neoplastic epithelium [26], as well as in cancer-derived 
RASSF1A-methylated A549 and H1299 cell lines for rescue experiments by re-expressing RASSF1A 
in such cells. While the loss-of-function of RASSF1A intervenes during early carcinogenesis stages, 
most of the data concerning RASSF1A’s role in apoptosis were derived from highly invasive cancer 
cells [43–46]. Using a clinically relevant dose of each drug [47], this study reported that paclitaxel-
treated HBEC displayed more increased apoptosis than gemcitabine-treated HBEC (Figure 1 and 
Figure S2, respectively). The differences in response patterns between the two drugs could be 
attributed to their ability to regulate specific components of cell death pathways. Paclitaxel-induced 
apoptosis is mainly mediated through the enforced activation of various caspases, including caspase 
3 and 7 [48–50]. Gemcitabine primarily causes Poly (ADP-ribose) polymerase(PARP) degradation 
through autophagy-regulated processes rather than apoptosis [51], which is why the results of 
single-agent gemcitabine chemotherapy are significantly improved by adding a PARP inhibitor 
in BRCA-1-deficient pancreatic and breast cancer cell lines [52–54]. 
The present results demonstrated that the knockdown of RASSF1A reduced the sensitivity of 
HBEC-3 cells to apoptosis after being treated with either paclitaxel or gemcitabine (Figure 1). In 
contrast, RASSF1A re-expression exerted the opposite impact, thereby promoting gemcitabine-
mediated apoptosis induction in RASSF1A-deficient H1299 cells (Figure S2). These functional studies 
support the anti-apoptotic role of RASSF1A [41]. Our work confirms the findings concerning an 
acquired resistance to paclitaxel after RASSF1A depletion (already observed in primary ovarian 
cancer cell models) [55], while elucidating how the RASSF1A loss could lead to a decreased 
gemcitabine effectiveness. 
Next, very surprisingly, RASSF1A was shown to be able to modulate IAP-2 expression in a YAP-
dependent manner (Figure 2). This outcome appeared to be quite specific, given that this study did 
not observe any significant expression changes in other IAP family members (IAP-1, survivin, or 
Bruce) through the modulation of RASSF1A expression (Figure 2) despite the fact that survivin 
expression has been previously reported to be increased in RASSF1A-depleted SKOV-3 ovarian 
cancer cells [46]. These data are consistent with the previous description of some IAPs as 
transcriptional targets of the transcriptional cofactor YAP-1 [13]. This latter result was previously 
reported by the authors to accumulate in the nucleus with transcriptional activation after RASSF1A 
knockdown [4]. Further, IAPs are known to be negative regulators employed by cancer cells in order 
to suppress apoptosis in numerous histological cancer subtypes. Of note, this suppression of 
apoptosis plays a central role upon multi-step carcinogenesis [13,56]. Interestingly, the 
overexpression of both IAP and YAP-1 genes was reported to exert a synergistic effect in promoting 
tumor-genesis [57]. Accordingly, using the samples collected from the Phase 3 IFCT-0002 trial 
patients [3], it was found that the YAP-1 nuclear localization in such samples was associated with a 
numerical, although not significant, decrease in OS (Figure S3). Most importantly, such strong YAP 
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expression was associated with a higher patients’ unresponsiveness rate to preoperative 
chemotherapy (Table 1). Unfortunately, this study could not quantify the IAP-2 expression in these 
same patient samples, owing to of a lack of reliable antibodies available for immunohistochemistry 
application of formalin-fixed paraffin-embedded (FFPE) samples. Furthermore, this sample 
collection is currently not in use, given that this specific analysis was not pre-specified or initially 
planned. 
Additionally, a cumulative effect was observed of either RASSF1A knockdown or RASSF1A re-
expression in combination with gemcitabine treatment, resulting in a dramatic increase or decrease 
in IAP-2 expression, respectively (Figure 3 and Figure S4). As RASSF1A has been clearly identified 
as a tumor suppressor gene [41], whereas IAPs are supposed to act as oncogenes [13], the authors 
suspect that this increase in IAP-2 could contribute to the impact of RASSF1A expression loss on 
tumor promotion. In support of this, the combined knockdown of RASSF1A and IAP-2 was able to 
restore the number of proliferative cells to the control cell level (Figure 4). Remarkably, either IAP-2 
knockdown alone or IAP-2 knockdown associated with RASSF1A forced re-expression and modestly 
inhibited cell proliferation. Of note, this observation highlights the context-dependent role IAPs play 
in controlling cell proliferation. For instance, it has been demonstrated that nuclear BIRC5/survivin, 
another IAP family member, regulates proliferation, whereas the cytoplasmic survivin protein pool 
acts to suppress apoptosis [58]. Published data reported that IAPs’ increased expression following 
gemcitabine treatment is able to suppress apoptosis, thus resulting in chemotherapy resistance 
[29,59]. Our data support that IAP-2 overexpression upon gemcitabine treatment likely proved to be 
the primary mechanism that counterbalances apoptotic signaling in HBEC-3 cells. 
Our further mechanistic studies demonstrated that not only did the depletion of both RASSF1A 
and IAP-2 decrease the migration and invasion ability of RASSF1A-depleted cells, but the increase in 
IAP-2 expression also seemed to be critical in the control of both migration and invasion through 
RASSF1A (Figure 5 and Figure S5). These data are in concordance with previous reports 
demonstrating that IAPs are deemed crucial regulators of tumor cell migration and metastasis [34]. 
For example, IAP-1 depletion has been reported to be able to suppress the Matrigel® invasion of PC3 
prostate cancer cells [60]. Collectively, these data underscore the pertinence of IAP-2 overexpression 
in mediating the effects of RASSF1A down-regulation. All this suggests that IAP-2 could be a critical 
downstream target of RASSF1A for controlling cell migration and invasion, although mechanistic 
studies are still pending to fully elucidate the mechanisms involved in such functional interactions. 
Besides its general role of an apoptosis regulator [61], RASSF1A is known to induce microtubule 
stabilization [38,62]. The inactivation of RASSF1A thus results in an increased sensitivity to 
microtubule-destabilizing drugs [37], and RASSF1A overexpression is surprisingly reminiscent of 
the cell effects produced by paclitaxel [63]. This study therefore, hypothesized that paclitaxel-
induced microtubule stabilization may likely be able to rescue the effects of RASSF1A depletion. The 
invasion assay was used to test such a hypothesis. Accordingly, compared to the untreated control 
and gemcitabine-treated cells, paclitaxel exposure was able to restore normal invasion in RASSF1A 
knockdown cells (Figure 6). These results corroborate previous study data that revealed a reduction 
in cell invasiveness following paclitaxel treatment administered at sub-lethal doses [64–66]. 
Conversely, other authors reported the opposite effect [67]. Most of the discrepancies pertaining to 
the pro- and anti-migratory effects of paclitaxel observed could be attributed not only to the 
differences in doses and cell subtypes employed, but also to the basic fact that appropriate 
microtubule dynamics are necessary to maintain normal cellular function. Since our data suggest a 
positive role of paclitaxel through microtubule stabilization, it is conceivable that microtubules might 
be indirectly involved in apoptosis regulation by recruiting, transporting, or both, the implicated 
proteins. Thus far, the interaction of the survivin protein with microtubules has been attributed to an 
increase in MT stability, which resulted in improved clinical outcomes [68]. Whether a similar 
function applies to other IAPs remains to be explored. 
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4. Materials and Methods 
4.1. Patients and Bio-IFCT 0002 Trial 
Between 2001 and 2005, 528 patients were recruited into the Phase 3 IFCT 0002 trial, which was 
approved by the corresponding ethics committee (CPPRB of University Hospital in Besançon, France, 
ethic code: 00/282). Specific informed consent deigned for biological studies was obtained (Bio-IFCT 
0002) beforehand. Two platin-based perioperative chemotherapy regimens, gemcitabine plus 
cisplatin and paclitaxel plus carboplatin, and two chemotherapy schedules were compared in 
patients with resectable Stage I or II NSCLC. In the preoperative arm (PRE), the patients received two 
courses of either chemotherapy regimen. The patients who did not respond discontinued 
chemotherapy and underwent surgical resection, whereas the patients with a partial response 
received two more cycles prior to surgical resection. In the perioperative arm (PERI), the patients 
received two courses of either chemotherapy regimen and underwent surgical resection. Only 
responder patients received two additional adjuvant cycles. The results of this Phase 3 trial have been 
presented elsewhere [69]. A Bio-IFCT 0002 study was designed by a steering committee, conducted 
according to a detailed protocol, and granted by the Programme Hospitalier de Recherche Clinique 
(PHRC) national 2001.  
4.2. Cell Culture, siRNA, Constructs, Transfection, and Treatments 
Immortalized human bronchial epithelial HBEC-3 and HBEC-3 RasV12 cells were kindly 
provided by Dr. Michaël White (UT Southwestern Medical Center, Dallas, TX, USA), as previously 
described [70]. They were grown in keratinocyte serum-free medium (KFSM) supplemented with 0.2 
ng/mL epidermal growth factor (EGFr) and 25 µg/mL bovine pituitary extracts (BPE) (Thermo Fisher 
Scientific, Rockford, IL, USA). Cancer-derived cell lines A549 and H1299 were purchased from the 
American Type Culture Collection (ATCC) and were grown in Dulbecco's Modified Eagle 
Medium (DMEM) supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum. Both KSFM 
and DMEM mediums were complemented by 100 U/mL penicillin, 100 µg/mL streptomycin and 2 
mM l-glutamine (Gibco, Life Technologies, Grand Island, NY, USA). The cultures were incubated at 
37 °C in a humidified atmosphere with 5% CO2. Where indicated, the cells were treated with the 
appropriate drug concentration (either 10 nM paclitaxel or 250 nM gemcitabine) for 24 h before 
analysis was conducted based on the previous study [47]. The 50 µM etoposide was employed as a 
positive control [27]. These drugs were purchased from Selleck Chemicals Co., Ltd. (Houston, TX, 
USA). 
The following RNAi oligonucleotides from Eurogentec® were employed: RASSF1A: 5’-
GACCUCUGUGGCGACUUCA(TT)-3’ and 5’-GAACGUGG ACGAGCCUGU(TT)-3’ [4]; to deplete 
IAP-1 expression, this study used 5’-GAAUGAAAGGCCAAGAGUU(TT)-3’ and 5’-
CAGAAAGCUUUGAAUACUA(TT)-3’ [71] and for IAP-2 5’-AAUGCAGAGUCAUCAAUUA(TT)-
3’ [72] and 5’-AAUGAUGGUUGAAGGUUACAU (TT)-3’ [73]. The mock siRNA was employed as 
the non-silencing negative control (Dharmacon, Thermo Scientific, Pittsburgh, PA, USA). Plasmids 
encoding wild-type RASSF1A (pcDNA3-RASSF1A) and control mimic (Addgene, Cambridge, MA, 
USA) have been described in the supplementary data section [4]. The introduction of siRNA and 
plasmids was performed using Lipofectamine RNAiMax (Invitrogen, Carlsbad, CA, USA) in 
accordance with the manufacturer's instructions at 30% and 70% of cell confluence, respectively. 
4.3. Preparation of RNA and RT-PCR 
The extraction of total RNA from treated and untreated cells was carried out using the illustra 
RNAspin mini® column (GE Healthcare, Bio-Sciences, Pittsburgh, PA, USA), according to the 
manufacturer’s instructions. Total RNA was treated with DNAse I (Invitrogen, Carlsbad, CA, USA) 
in order to remove contaminating genomic DNA. The RNA concentrations were determined using 
spectrophotometer Nanodrop® 2000c. The total RNA (250 ng) was reverse-transcribed with random 
primers and 200 IU M-MLV reverse transcriptase at 37 °C for 90 min, followed by 5 min of 
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dissociation at 70 °C with Mastercycler Eppendorf®. The resulting cDNAs were diluted (1/10) and 
used as templates. Polymerase chain reaction (PCR) was performed in a Mx3005P QPCR system 
(Agilent Technology) with 5pmol of each primer set (Table 2) and iQTM SYBR Green Supermix (Bio-
Rad, Hercules, CA, USA) as follows: 95 °C for 5 min, followed by 40 cycles at 95 °C for 1 min, and 
annealing/extension at 60 °C for 60 s. Furthermore, S16 was used as an internal control. Positive 
standards and reaction mixtures lacking the reverse transcriptase were employed routinely as 
controls for each RNA sample. The relative quantification was calculated using the ΔΔCt method. 
Table 2. Primers used for RT-PCR in this work. 
Target Primers (5’  3‘) 
RASSF1A 
Forward (F): GGG GTC GTC CGC AAA GGC C 
Reverse (R): GGG TGG CTT CTT GCT GGA GGG 
IAP-1 
F: CCT GGA TAG TCT ACT AAC TGC CT 
R: GCT TCT TGC AGA GAG TTT CTG AA 
IAP-2 
F: CAG ATT TGG CAA GAG CTG GT 
R: ATT CGA GCT GCA TGT GTC T 
Actin 
F: CAA CCG TGA AAA GAT GAC CCA G 
R: ATG GGC ACAGTG TGG GTG AC 
4.4. Antibodies 
The following antibodies were used: monoclonal mouse anti-human Cytochrome c (BD 
Transduction Laboratories, San Jose, CA, USA), monoclonal mouse anti-human RASSF1A 
(Ebioscience, San Diego, CA, USA) and monoclonal rabbit anti-human PARP (Cell Signaling 
Technology, Beverly, MA, USA). 
4.5. Immunofluorescence (IF), Immunohistochemistry (IHC), and Image Analysis 
For IF studies, the cells were seeded on coverslips in 24-well tissue culture trays at a density of 
2 × 104. Following 48 h, the cells were washed with PBS and fixed with 4% paraformaldehyde for 20 
minutes at 37 °C. The cells were then permeabilized with frozen methanol for 10 minutes and blocked 
with 4% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for 1 hour and stained with 
primary antibodies at 4 °C overnight. After being washed with PBS, the cells were stained with either 
Alexa-488-conjugated or Alexa-555-conjugated secondary antibodies (Molecular Probes, Invitrogen, 
Eugene, OR, USA) for 1 hour at room temperature (RT) and with DAPI (4,6 diamidino-2-
phenylindole) (Santa Cruz Biotechnology, Dallas, TX, USA). Digital pictures were captured using a 
high-throughput confocal microscopy (FluoView FV1000, Olympus, Wendenstrasse, Germany). 
The IHC was performed, as described previously [70,74]. Briefly, 443 out of 492 
paraffin-embedded blocks issued from the Phase 3 IFCT-002 trial were collected for this study. A 
YAP antibody was used at 1:100 dilution. The internal positive controls were systematically 
performed for each tumor series (immuno-stained basal cells). The staining intensities were evaluated 
in a blinded manner at 40× magnification and were scored using marker-specific 0–3 scales (0: 
negative, 1: weak, 2: moderate, and 3: strong). An overall IHC composite score was calculated based 
on the sum of the staining intensity (0–3) multiplied by the distribution (0–100%) from all parts of the 
slide, thereby providing an H-score between 0 and 300. 
4.6. BrdU Incorporation Assay 
The effect of chemotherapy drugs on cell growth was evaluated using a BrdU incorporation 
assay kit in accordance with the manufacturer’s instructions (1/500 dilution) (cat. no. 2750, Millipore, 
Billerica, MA, USA). BrdU, a synthetic thymidine analogue, can be incorporated into newly 
synthesized DNA, providing a test of DNA replication as an indirect measure of cell proliferation. 
The BrdU incorporation was detected by adding a peroxidase substrate. Spectrophotometric 
detection was performed at 450 nm wavelength. 
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4.7. Apoptosis Measurement 
DNA fragmentation and caspase-3/7 activation were assayed using the Cell Death Detection 
ELISA Plus Kit (Roche Diagnostics, Mannheim, Germany) and the Caspase-Glo 3/7 Luminescence 
Assay (Promega Corp., Madison, WI, USA), respectively, according to the manufacturer’s 
instructions. 
4.8. Wound-Healing Assay 
The transfected cells were seeded on collagen IV-coated plates (BD BioCoat Matrigel® Invasion 
Chamber, 8.0-µm pore size for 24-well plates) (BD Biosciences, Bedford, MA, USA), grown to 
confluence and pretreated with mitomycin C (1 µg/mL) over 12 hours before an artificial “wound” 
was created by scratching with a P-200 pipette tip. This point was considered the “0 h,” with the 
width of the wound photographed under a microscope (×10). The cells were then allowed to close 
the wound and were photographed at six hours. Wound healing was measured as µm/hour by 
calculating the reduction in the wound’s width between 0 and 6 h. 
4.9. D Migration and Invasion Assay 
The total of 25 × 103 cells in 250 µL serum-free medium were placed in the upper chambers of 
24-well Transwell plates containing a cell culture inserted with 8µm pore size and Matrigel® 
(invasion, BD BioCoat Matrigel® Invasion Chamber, BD Biosciences, Bedford, MA, USA) or not (3D 
migration). The lower chamber was filled with 700 µL complete media. After 48 h of incubation, the 
non-migrating cells on the top were removed using cotton swabs and the migrating cells on bottom 
surface of the filter were stained using crystal violet. The quantification of the migration and invasion 
assay was performed by counting the cells on the filter’s lower surface under an inverted microscope 
at ×20 magnification. The assays were performed in triplicate, with data presented as the average 
number of invading cells. 
4.10. Statistical Analysis 
For the cells, the data were expressed as the means ± SEM of experiments, independently 
conducted three times. All statistical analyses were performed using GraphPad Prism 4, a GraphPad 
Software program (San Diego, CA, USA). The data were analyzed using a two-tailed Student’s t-test 
for single comparison or one-way ANOVA followed by Dunnett’s multiple comparison analysis. The 
differences were considered significant at the p < 0.05 level. 
For YAP staining in samples from the Bio-IFCT0002, the characteristics of patients with (n = 362) 
and without (n = 130) YAP IHC were compared using chi-squared tests or Fisher’s exact test for 
qualitative variables, with Student’s t-tests applied for quantitative variables. The associations 
between the YAP expression or subcellular localization and clinical characteristics were evaluated 
using Chi-squared, Fisher’s exact or Student’s t-tests. 
The prognosis values for disease-free survival (DFS) and OS based on IHC scores and subcellular 
localization were assessed using Cox models. The interaction tests were employed to evaluate 
predictive values. The IHC scores were first studied as continuous variables ranging from 0 to 300. 
The median follow-up was estimated using the reverse Kaplan–Meier method. The multivariate Cox 
models were used to adjust for the patients’ characteristics associated with the corresponding 
outcomes (DFS, or OS) at p < 0.20 in the univariate analysis. The IHC score was dichotomized 
(negative/positive) as indicated by a fractional polynomial analysis, and the median value selected in 
YAP analyses by this methodology. A two-step bootstrap re-sampling analysis was performed in 
order to validate the prognostic model [75]. The data were analyzed using SPSS for Windows 
Evaluation Version 15.0 (SPSS, Inc., Chicago, IL, USA 2006), the multivariable fractional polynomials 
(MFP) package of R software (R package Version 1.4.0, original by Gareth Ambler and modified by 
Axel Benner, 2007) and SAS 9.3 (SAS Institute Inc., Cary, NC, USA). 
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5. Conclusions 
Despite advances in surgical techniques, radiotherapy, chemotherapy and most recently, 
immunotherapy using immune checkpoint inhibitors, NSCLC is still one of the primary causes of 
cancer-related deaths worldwide [76]. The intrinsic or acquired cellular adaptations to therapy are 
major factors contributing to treatment failures [77]; identifying these molecular signaling 
mechanisms appears critical for identifying druggable targets that may either be predictors of 
therapeutic response or mediators of resistance. Here, this study showed, for the first time, that 
RASSF1A depletion reduces the ability of bronchial epithelial or lung cancer cells to undergo 
apoptosis via increasing IAP-2 protein expression and reducing apoptosis-related proteins. The 
authors have likewise demonstrated that the increase in IAP-2 content in the RASSF1A-depleted 
HBEC cells is exacerbated by gemcitabine, the administration of which should thus be less efficient 
to patients with NSCLC exhibiting RASSF1A promoter gene methylation. Finally, this study 
introduces IAP-2 as a critical mediator for the cell consequences of RASSF1A’s loss of expression, 
which is found in the tumors of up to 30% of NSCLC patients. Whether IAP-2 could represent a new 
putative target for cytotoxic drugs aiming at specifically treating NSCLC patients with RASSF1A 
promoter methylation tumors remains to be established. Indeed, emerging evidence derived from 
recent clinical and experimental studies [78,79] highlights the relevance of pharmacologic inhibitors 
of IAPs as potential therapeutic agents for cancer therapy. Our results suggest that chemotherapy 
combined with IAP inhibitors are likely to show elective efficacy in patients with an inactive tumor 
suppressor gene RASSF1A. 
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